DDInter527 DDInter1376
Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997]
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Dextromethorphan {u} (Compound) resembles {v} (Compound) Levallorphan
Dextromethorphan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydromorphone
Dextromethorphan {u} (Compound) binds {v} (Gene) CYP3A4
Dextromethorphan {u} (Compound) upregulates {v} (Gene) PYCR1
Dextromethorphan {u} (Compound) palliates {v} (Disease) amyotrophic lateral sclerosis
Dextromethorphan {u} (Compound) is included by {v} (Pharmacologic Class) Uncompetitive NMDA Receptor Antagonists
Dextromethorphan {u} (Compound) downregulates {v} (Gene) GJA1
Dextromethorphan {u} (Compound) causes {v} (Side Effect) Abdominal discomfort
Dextromethorphan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Memantine
Dextromethorphan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rolapitant
Dextromethorphan (Compound) resembles Levallorphan (Compound)
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone
Dextromethorphan (Compound) binds CYP3A4 (Gene)
Dextromethorphan (Compound) upregulates PYCR1 (Gene)
Dextromethorphan (Compound) palliates amyotrophic lateral sclerosis (Disease)
Dextromethorphan (Compound) is included by Uncompetitive NMDA Receptor Antagonists (Pharmacologic Class)
Dextromethorphan (Compound) downregulates GJA1 (Gene)
Dextromethorphan (Compound) causes Abdominal discomfort (Side Effect)
Dextromethorphan may cause a minor interaction that can limit clinical effects when taken with Memantine
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant